Description

Riboxin (Inosine) Tablets 200 mg, #50

Riboxin, containing the active ingredient inosine, is a metabolic agent used to support cardiovascular health and enhance energy metabolism. It is widely used in cardiology for its protective and restorative effects on heart tissue and energy processes in the body. Each pack contains 50 tablets, with each tablet delivering 200 mg of inosine.

Composition

• Active ingredient: Inosine – 200 mg per tablet
• Excipients: starch, lactose, calcium stearate, cellulose (may vary by manufacturer)

Pharmacological Group

Metabolic agent; nucleoside derivative with cardioprotective and antihypoxic properties.

Mechanism of Action

Inosine serves as a precursor to adenosine and supports the synthesis of nucleotides and ATP, the primary cellular energy carrier. It enhances myocardial metabolism, improves oxygen utilization, and activates metabolic enzymes in the Krebs cycle. Riboxin may also stimulate tissue regeneration and protect against ischemic damage by stabilizing cell membranes and reducing oxidative stress.

Therapeutic Indications

• Coronary heart disease (angina pectoris, post-infarction state)
• Myocardial dystrophy and cardiomyopathies
• Arrhythmias (especially caused by cardiac glycoside use)
• Hepatic diseases (fatty liver, hepatitis, cirrhosis – as part of combination therapy)
• Postoperative support in cardiac surgery

Dosage and Administration

• Initial dose: 600–800 mg per day (e.g., 1 tablet 3–4 times daily before meals)
• Maintenance dose: up to 1200–2400 mg per day divided into 2–4 doses
• Course duration: typically 4–12 weeks depending on clinical response

Always follow physician guidance for individual dosing.

Contraindications

• Hypersensitivity to inosine or excipients
• Gout or hyperuricemia
• Urolithiasis with uric acid stones

Precautions

• Monitor serum uric acid levels during long-term therapy
• Use with caution in patients with renal dysfunction
• Not recommended during pregnancy or lactation unless prescribed

Possible Side Effects

• Hyperuricemia and gout exacerbation
• Skin rash, itching (allergic reactions)
• Gastrointestinal discomfort: nausea, vomiting, epigastric pain
• Flushing (warm sensation, skin redness)

Drug Interactions

• May potentiate effects of antiarrhythmic agents such as digoxin
• Possible enhancement of anticoagulant effects when used with heparin or warfarin
• Incompatible with acids and alcohol-based solutions in injectable forms (not relevant to tablets)

Overdose

Symptoms may include hypotension, tachycardia, increased uric acid levels, and gastrointestinal upset. Treatment is symptomatic and supportive. Seek emergency medical care in case of overdose.

Storage Conditions

• Store in a dry place at temperatures below 25°C
• Protect from direct light and moisture
• Keep out of reach of children

Scientific References

• Inosine and metabolic cardioprotection – PubMed
• Therapeutic use of purine nucleosides in cardiovascular diseases

Manufacturer

Multiple manufacturers produce Riboxin globally, including Valenta Pharmaceuticals (Russia), Farmak (Ukraine), and others.

Prescription Status

Varies by country: available OTC in some regions; prescription-only in others.

Disclaimer

This summary is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance tailored to your individual health condition.